MNG713
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.549
- MYC_TARGETS_V2+0.503
- E2F_TARGETS+0.458
- G2M_CHECKPOINT+0.430
- DNA_REPAIR+0.296
- INTERFERON_ALPHA_RESPONSE+0.286
- MITOTIC_SPINDLE+0.261
- MYC_TARGETS_V1+0.261
- GLYCOLYSIS+0.259
- MTORC1_SIGNALING+0.259
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.363
- PROTEIN_SECRETION-0.335
- ANDROGEN_RESPONSE-0.289
- UV_RESPONSE_DN-0.284
- KRAS_SIGNALING_UP-0.277
- TGF_BETA_SIGNALING-0.198
- WNT_BETA_CATENIN_SIGNALING-0.165
- ALLOGRAFT_REJECTION-0.150
- HEDGEHOG_SIGNALING-0.143
- COMPLEMENT-0.112
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1115 | — | — | 0.861 |
| 2 | C3N-01419 | — | cohortA1 | 0.843 |
| 3 | TCGA-XF-A9T6-01A-11R-A42T-07 | — | — | 0.841 |
| 4 | MNG626 | — | — | 0.838 |
| 5 | 48128da3-329b-45c5-be65-c8cbeccddb97 | — | — | 0.813 |
| 6 | MNG358 | — | — | 0.809 |
| 7 | 652298ba-554a-4fad-9d8b-aceaee37f9f2 | — | — | 0.808 |
| 8 | MNG774 | — | — | 0.807 |
| 9 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.805 |
| 10 | SRR8518230 | — | E | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.549 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.503 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.458 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.296 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.286 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.261 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.261 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.259 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.259 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.256 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.246 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.194 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.194 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.183 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.123 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.116 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.108 | Inavolisib | — uncovered |